BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kwo PY, Puenpatom A, Zhang Z, Hui SL, Kelley AA, Muschi D. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PLoS One 2019;14:e0218759. [PMID: 31437170 DOI: 10.1371/journal.pone.0218759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Eames JR, Tran B. Hepatitis C. Physician Assistant Clinics 2021;6:555-68. [DOI: 10.1016/j.cpha.2021.05.002] [Reference Citation Analysis]
2 Valencia J, Lazarus JV, Ceballos FC, Troya J, Cuevas G, Resino S, Torres-Macho J, Ryan P. Differences in the hepatitis C virus cascade of care and time to initiation of therapy among vulnerable subpopulations using a mobile unit as point-of-care. Liver Int 2021. [PMID: 34767680 DOI: 10.1111/liv.15095] [Reference Citation Analysis]
3 Kamali I, Shumbusho F, Barnhart DA, Nyirahabihirwe F, Gakuru JP, Dusingizimana W, Nizeyumuremyi E, Habinshuti P, Walker S, Makuza JD, Serumondo J, Nshogoza Rwibasira G, Ndahimana JD. Time to complete hepatitis C cascade of care among patients identified during mass screening campaigns in rural Rwanda: a retrospective cohort study. BMC Infect Dis 2022;22:272. [PMID: 35313817 DOI: 10.1186/s12879-022-07271-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Wang AE, Hsieh E, Turner BJ, Terrault N. Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts. J Gen Intern Med 2022. [PMID: 35484367 DOI: 10.1007/s11606-022-07628-9] [Reference Citation Analysis]
5 Kattakuzhy S, Rosenthal E. To Eliminate Hepatitis C in People Who Inject Drugs, Stop Ignoring Drug-user Health. Clin Infect Dis 2021;73:e119-21. [PMID: 32445562 DOI: 10.1093/cid/ciaa607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Javanbakht M, Archer R, Klausner J. Will prior health insurance authorization for medications continue to hinder hepatitis C treatment delivery in the United States? Perspectives from hepatitis C treatment providers in a large urban healthcare system. PLoS One 2020;15:e0241615. [PMID: 33147293 DOI: 10.1371/journal.pone.0241615] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Karmarkar T, Padula WV, Gaskin DJ, Watson E, Rodriguez CV. Characteristics associated with time-to-treatment initiation for chronic Hepatitis C with new direct acting antivirals. Pharmacoepidemiol Drug Saf 2021;30:86-96. [PMID: 33090666 DOI: 10.1002/pds.5138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Spradling PR, Zhong Y, Moorman AC, Rupp LB, Lu M, Gordon SC, Teshale EH, Schmidt MA, Daida YG, Boscarino JA; Chronic Hepatitis Cohort Study (CHeCS) Investigators. Psychosocial Obstacles to Hepatitis C Treatment Initiation Among Patients in Care: A Hitch in the Cascade of Cure. Hepatol Commun 2021;5:400-11. [PMID: 33681675 DOI: 10.1002/hep4.1632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Shakeri A, Srimurugathasan N, Suda KJ, Gomes T, Tadrous M. Spending on Hepatitis C Antivirals in the United States and Canada, 2014 to 2018. Value Health 2020;23:1137-41. [PMID: 32940230 DOI: 10.1016/j.jval.2020.03.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
10 Busingye D, Chidwick K, Simpson V, Dartnell J, J Dore G, Balcomb A, Blogg S. The changing characteristics of patients with chronic hepatitis C prescribed direct acting antiviral medicines in general practice since listing of the medicines on the Australian Pharmaceutical Benefits Scheme. JGH Open 2021;5:813-9. [PMID: 34263077 DOI: 10.1002/jgh3.12593] [Reference Citation Analysis]